23andMe Holding Co. (ME) Misses Q3 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. SKYD
6. SPY
7. RCKT
8. CRWV
9. NVDA
10. CRBU

Go back to 23andMe Holding Co. (ME) Misses Q3 EPS by 5c

23andMe Reports FY2022 Third Quarter Financial Results

February 10, 2022 4:04 PM EST

Third quarter revenue of $57 million Therapeutics group advances first wholly-owned immuno-oncology antibody into clinical trials Vision of genetics-based primary care offers potential for millions of people to live healthier lives

SUNNYVALE, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the third quarter (Q3) of its fiscal year 2022 (FY2022), which ended December 31, 2021. 23andMe is the only company with multiple FDA authorizations for... More